文献速递脑血管病

脑静脉血栓形成后初始直接口服抗凝药与华法林的靶试验模拟

Initial Direct Oral Anticoagulants Versus Warfarin After Cerebral Venous Thrombosis: A Target Trial Emulation
RSS 订阅 · Stroke

该研究基于中国多中心脑静脉血栓形成注册登记,采用靶试验模拟方法比较初始DOAC与华法林预防1年症状性复发性VTE的疗效。在2476例患者中,DOAC组1年复发风险为3.74%,华法林组为5.47%,风险差为−1.73个百分点(95%CI −3.76至0.30),满足预设非劣效标准(P非劣效=0.004)。

要点

  • 脑静脉血栓形成后初始DOAC治疗在1年症状性复发性VTE预防上非劣于华法林。
  • 重叠加权后1年复发风险DOAC组3.74%、华法林组5.47%,风险差−1.73个百分点。
  • 出血结局为探索性分析,不能得出安全性比较结论。

核心结论

  • 在因脑静脉血栓形成而选择口服抗凝药的患者中,初始DOAC治疗在1年症状性复发性VTE预防方面满足相对于华法林的非劣效标准。

研究设计与样本

  • 基于中国双向多中心脑静脉血栓形成注册登记(回顾性阶段2015–2022,前瞻性阶段2023–2025)的靶试验模拟。
  • 纳入影像确诊的成人脑静脉血栓形成患者,在诊断后30天内启动DOAC或华法林,共2476例,其中DOAC组942例、华法林组1534例。
  • 采用倾向评分重叠加权,加权Fine-Gray模型将死亡作为竞争事件。
  • 预设临床可接受非劣效界值为1年复发性VTE风险绝对增加1.5个百分点,对应主要Fine-Gray分析的相对界值约1.50。

主要发现

  • 1年内症状性复发性VTE在DOAC组发生36例、华法林组73例。
  • 重叠加权后1年复发风险分别为3.74%和5.47%,风险差为−1.73个百分点(95%CI −3.76至0.30)。
  • DOAC治疗相较于华法林的亚分布风险比为0.67(95%CI 0.37–1.21;P=0.184),满足预设非劣效标准(P非劣效=0.004)。
  • 1年内大出血罕见(DOAC组0例 vs 华法林组1例)。
  • 临床非大出血分别为18例 vs 34例,任何出血分别为48例 vs 75例。

关键数值与推荐

  • 主要疗效结局为1年内症状性复发性VTE。
  • 非劣效界值为1年复发风险绝对增加1.5个百分点,相对界值约1.50。
  • DOAC组药物包括利伐沙班701例、达比加群121例、阿哌沙班113例、艾多沙班7例。

临床怎么用

  • 对于脑静脉血栓形成后需口服抗凝的患者,初始DOAC可作为华法林的替代选择,以预防1年症状性复发性VTE。
  • 出血安全性数据为探索性,临床决策时仍需结合患者个体出血风险综合评估。

局限性

  • 出血结局为探索性分析,不能就安全性比较或等效性得出结论。
  • 研究为靶试验模拟,可能存在未测量混杂。
  • DOAC组内不同药物样本量差异较大,未报告各药物单独比较结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Stroke, Ahead of Print. BACKGROUND:Vitamin K antagonists have traditionally been used after cerebral venous thrombosis, whereas direct oral anticoagulants (DOACs) are increasingly prescribed. Whether DOACs are noninferior to warfarin for preventing 1-year symptomatic recurrent venous thromboembolism (VTE) remains uncertain.METHODS:We conducted a registry-based target trial emulation in a bidirectional multicenter Chinese cerebral venous thrombosis registry (retrospective phase, 2015–2022; prospective phase, 2023–2025). Eligible patients were adults with imaging-confirmed cerebral venous thrombosis who initiated either a DOAC or warfarin within 30 days after diagnosis. Time zero was the date of the first oral anticoagulant prescription. The primary efficacy outcome was symptomatic recurrent VTE within 1 year. Propensity score overlap weighting was used, and weighted Fine-Gray models treated death as a competing event. The clinically acceptable noninferiority margin was defined as an absolute increase of 1.5 percentage points in 1-year recurrent VTE risk, corresponding approximately to a relative margin of 1.50 for the primary Fine-Gray analysis.RESULTS:Among 2476 eligible patients, 942 initiated a DOAC (rivaroxaban, n=701; dabigatran, n=121; apixaban, n=113; edoxaban, n=7) and 1534 initiated warfarin. Within 1 year, symptomatic recurrent VTE occurred in 36 and 73 patients, respectively. The overlap-weighted 1-year recurrence risks were 3.74% and 5.47%, corresponding to a risk difference of −1.73 percentage points (95% CI, −3.76 to 0.30). DOAC treatment was associated with a lower subdistribution hazard ratio of 0.67 compared with that of warfarin ([95% CI, 0.37–1.21];P=0.184), meeting the prespecified noninferiority criterion (Pfor noninferiority=0.004). Major bleeding was rare within 1 year (0 versus 1 patient). Clinical nonmajor bleeding occurred in 18 versus 34 patients, and any bleeding occurred in 48 versus 75 patients.CONCLUSIONS:Among patients with cerebral venous thrombosis selected for oral anticoagulation, initial treatment with a DOAC met the noninferiority criterion relative to warfarin for the prevention of symptomatic recurrent VTE at 1 year. Findings regarding bleeding outcomes were exploratory and do not permit conclusions regarding comparative safety or equivalence.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Stroke:Initial Direct Oral Anticoagulants Versus Warfarin After Cerebral Venous Thrombosis: A Target Trial Emulation

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。